Listed by the USPTO as CORNET, JEAN P
Tech Center 1600 • Art Units: 1614 1616 1628
This examiner grants 42% of resolved cases
CORNET, JEAN P examines in Tech Center 1600 and Art Unit 1614. The profile covers 1,199 resolved cases, with an allowance rate of 41.8%. The median time to allowance is 1,120 days. Together, these figures show a substantial record with a lower allowance outcome than a majority-allowance profile would indicate, without supplying an Art Unit baseline for further comparison.
The interview lift is 47.3%, making interviews a notable consideration when planning responses in this profile. The listed companies are University of Florida Research Foundation Inc., Insilico Medicine Ip Limited, and Amazentis SA. The listed firms are WILSON SONSINI GOODRICH & ROSATI, FOLEY HOAG, LLP (General), and Meunier Carlin & Curfman LLC. These entities provide practical reference points for counsel with related matters.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18720572 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18007308 | THERAPEUTIC USES OF GLUCOCORTICOIDS WITH ANABOLIC EFFECTS IN SKELETAL MUSCLE | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18806773 | INHIBITORS OF TRPC6 FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18006584 | USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND FOR PREVENTING, ALLEVIATION, OR TREATING MASTOCYTOSIS | Final Rejection | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18376308 | DISINFECTING COMPOSITION, APPLICATOR, AND METHOD OF DISINFECTING | Final Rejection | Medline Industries, LP |
| 18728990 | PLASMA KALLIKREIN INHIBITORS | Non-Final OA | Merck Sharp & Dohme LLC |
| 17355727 | COMPOSITIONS AND METHODS FOR INDUCING APPENDAGE AND LIMB REGENERATION | Final Rejection | California Institute of Technology |
| 18719825 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | Non-Final OA | Trustees of Tufts College |
| 18648062 | THERAPEUTIC COMPOUNDS | Non-Final OA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY |
| 18728706 | COMPOSITION, METHOD FOR MICROORGANISM GROWTH SUPPRESSION IN COMPOSITION FOR ORAL USE, AND AGENT FOR POTENTIATION OF MICROORGANISM-GROWTH-SUPPRESSING EFFECT OF QUERCETIN OR GLYCOSIDE THEREOF | Final Rejection | SUNTORY HOLDINGS LIMITED |
| 18724520 | METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING STRESS-RELATED DISORDER | Non-Final OA | Yale University |
| 18257680 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy41.8% of resolved applications examined by Jean P Cornet were allowed (1,199 resolved cases), compared with 48.7% across Art Unit 1614 over the last five years.
This examiner's interview lift is +47.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jean P Cornet took 1,120 days on average from filing to allowance.
Jean P Cornet examines applications in Art Unit 1614 in Tech Center 1600 (Biotechnology & Pharmaceuticals).